Pivanex

Pivanex (AN-9), a derivative of Butyric acid, is an orally active HDAC inhibitor. Pivanex down-regulates bcr-abl protein and enhances apoptosis. Pivanex has antimetastic and antiangiogenic properties[1].

Product Specifications

CAS Number

[122110-53-6]

Product Name Alternative

AN-9; Pivalyloxymethyl butyrate

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Bcr-Abl; HDAC

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pivanex.html

Purity

95.0

Solubility

DMSO : ≥ 100 mg/mL

Smiles

CCCC(OCOC(C(C)(C)C)=O)=O

Molecular Formula

C10H18O4

Molecular Weight

202.25

Precautions

H302, H315, H319, H335

References & Citations

[1]Rabizadeh E, et al. Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line. Leuk Res. 2007 Aug;31 (8) :1115-23. Epub 2007 Jan 30.|[2]Batova A, et al. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood. 2002 Nov 1;100 (9) :3319-24.|[3]Edwards JD, et al. Effect of the Butyrate Prodrug Pivaloyloxymethyl Butyrate (AN9) on a Mouse Model for Spinal Muscular Atrophy. J Neuromuscul Dis. 2016 Nov 29;3 (4) :511-515.